Learn how to find the current needed to deflect a compass needle in this step-by-step physics tutorial! Explore the principles of magnetic fields, current-carrying wires, and the interaction with a ...

Compass Pathways is rated a Hold due to high risk, funding needs, and the need for further data before reassessing the thesis ...

Compass Pathways has reported another phase 3 win for its psilocybin therapy in treatment-resistant depression, sending the ...

Compass’ private exclusive listings feature may have started a tech race nationally, but it joined several similar models already existing in Texas.

That didn’t take long. Moderna said this morning that the FDA will now review its experimental mRNA flu vaccine, reversing its decision denying a review because of a dispute over the vaccine’s ...

Compass Point is adopting a bullish stance on Nebius Group . The firm initiated the artificial intelligence infrastructure stock with a buy rating and price target of $150, implying upside of 54%.

The company is currently conducting clinical trials of COMP360, a proprietary synthetic formulation of psilocybin, designed for treatment-resistant depression.

Test drive the research and analytics tools trusted by thousands of users. Get two weeks of access, one-on-one walkthrough, personal specialist support.